Denali Therapeutics Inc. (DNLI)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Revenue fell year over year to about $17.8 million in Denali Therapeutics’ third fiscal quarter of 2026, which it reported on November 3, 2026, as the clinical-stage biotech continues advancing programs across neurodegenerative and related diseases including Parkinson’s disease and ALS as well as Hunter syndrome. Profitability remained negative, with operating income of roughly -$126.8 million under GAAP, reflecting the company’s ongoing investment profile as it develops candidates such as BIIB122/DNL151, DNL310, DNL343, and other earlier-stage programs. Consensus for the next period calls for EPS of -$0.64 on revenue of $27.5 million.
About Denali Therapeutics Inc.
Denali Therapeutics Inc. is a U.S.-focused biotechnology company listed on NASDAQ as DNLI that develops drug candidates for neurodegenerative and related diseases. In qualitative terms, it is a clinical-stage healthcare business built around advancing targeted therapies, with programs that span Parkinson's disease, ALS, Hunter syndrome, multiple sclerosis, Alzheimer's disease, and cutaneous lupus erythematosus.
Today's Snapshot
DNLI closed 2.2% higher on heavier trading than usual. Denali Therapeutics launched AVLAYAH, a new treatment.
Trading Volume
Above 10d avg 1.4M
2M
vs S&P 500 Today
Outperforming Market
+2.48%
Updated: November 18, 2026 at 21:22 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$18.86 - $20.62Sell
- RSI (14)42.65Neutral
- Stochastic %K (14, 3, 3)13.68Buy
- MACD Level (12, 26)-0.29Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.